<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096351</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2021/EF-01</org_study_id>
    <nct_id>NCT05096351</nct_id>
  </id_info>
  <brief_title>Immunological Reaction of the Recipient After Cold-stored Saphenous Venous Allograft (Bioprotec)</brief_title>
  <acronym>REACIMALLOGV</acronym>
  <official_title>Immunological Reaction of the Recipient After Cold-stored Saphenous Venous Allograft (Bioprotec)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigators propose to perform a blood test before and after allograft placement&#xD;
      in all patients receiving a cold-stored venous allografts at the University Hospital of Nîmes&#xD;
      to study the occurrence of FVFA-related ASD in these patients.&#xD;
&#xD;
      The aim of this work is to characterize a possible immune reaction generated by the&#xD;
      implantation of venous allografts prepared according to the BIOPROTEC method. In case of a&#xD;
      proven immune reaction, the study will allow a modification of our current attitude and to&#xD;
      exclude patients potentially eligible for renal transplantation at the time of venous&#xD;
      allograft placement, or to perform in these patients an allo-compatibility test with the&#xD;
      venous allograft preoperatively and thus protect these patients from an increased risk of&#xD;
      subsequent organ transplant rejection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of donor specific antibodies after venous allograft</measure>
    <time_frame>1 month</time_frame>
    <description>Presence/absence of donner anti-HLA antibodies in patient blood, detected using Luminex assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allograft anomalies linked to allograft rejection</measure>
    <time_frame>1 month</time_frame>
    <description>Inflammation, thrombosis, aneurysms progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft anomalies linked to allograft rejection</measure>
    <time_frame>6 month</time_frame>
    <description>Inflammation, thrombosis, aneurysms progression</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allograft</condition>
  <condition>Cold Temperature</condition>
  <condition>Saphenous Vein</condition>
  <arm_group>
    <arm_group_label>Patients with venous allograft</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies</description>
    <arm_group_label>Patients with venous allograft</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, cell pellets, venous tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving a scheduled venous allograft within the CHU of Nîmes for an arterial&#xD;
        bypass in the lower limb or an arteriovenous bypass in the upper limb within the framework&#xD;
        of the creation of arteriovenous fistulas in dialysis patients, in the absence of available&#xD;
        autologous venous material.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Patients receiving a scheduled venous allograft within the CHU of Nîmes for an&#xD;
             arterial bypass in the lower limb or an arteriovenous bypass in the upper limb within&#xD;
             the framework of the creation of arteriovenous fistulas in dialysis patients, in the&#xD;
             absence of available autologous venous material.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in a category 1 interventional study, or is in a period&#xD;
             of exclusion determined by a previous study&#xD;
&#xD;
          -  The subject has already been included in the study&#xD;
&#xD;
          -  The subject refuses to participate&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Patient previously having received a venous allograft or organ transplant&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding patients&#xD;
&#xD;
          -  Presence of donor-specific antibodies in HLA-immunized patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elsa Faure</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elsa Faure</last_name>
    <phone>04.66.68.39.30</phone>
    <email>elsa.faure@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Elsa Faure</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Picard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

